Skip to main content
. 2017 Jan 3;8(8):12764–12774. doi: 10.18632/oncotarget.14463

Figure 5. Effects of HHT, ibrutinib, HHT+ibrutinib on cell cycle distribution in AML cells.

Figure 5

(A) MV4-11 and MOLM-13 cells were treated with 4 nM HHT and/or 1.25 μM ibrutinib for 24 h. (B) MV4-11 and MOLM-13 cells were treated with 8 nM HHT or/and 2.5 μM ibrutinib for 24 h. The cells were stained with propidium iodide and subjected to flowcytometry analysis to determine cell cycle distribution. (C and D) Soluble proteins P21, CCDN2, CCDN3, CDK4, CDK6, CDK2 and β-actin were analyzed by Western blotting analyses at the indicated concentrations for 24 h.